ERNA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of ERNA is average, but there are quite some concerns on its profitability. ERNA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

ERNA had negative earnings in the past year.
ERNA had a negative operating cash flow in the past year.
In the past 5 years ERNA always reported negative net income.
ERNA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -297.41%, ERNA is not doing good in the industry: 91.05% of the companies in the same industry are doing better.
ERNA has a Return On Equity of -514.17%. This is in the lower half of the industry: ERNA underperforms 75.24% of its industry peers.

		Industry Rank	Sector Rank
ROA	-297.41%
ROE	-514.17%
ROIC	N/A

ROA(3y)-333.38%

ROA(5y)-301.4%

ROE(3y)-1264.52%

ROE(5y)-959.07%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of ERNA (100.00%) is better than 99.24% of its industry peers.
ERNA's Gross Margin has improved in the last couple of years.
ERNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	100%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y6.07%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ERNA has more shares outstanding
The number of shares outstanding for ERNA has been increased compared to 5 years ago.
ERNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ERNA has an Altman-Z score of -58.27. This is a bad value and indicates that ERNA is not financially healthy and even has some risk of bankruptcy.
ERNA has a worse Altman-Z score (-58.27) than 90.86% of its industry peers.
There is no outstanding debt for ERNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-58.27

ROIC/WACCN/A

WACC7.47%

2.3 Liquidity

A Current Ratio of 1.58 indicates that ERNA should not have too much problems paying its short term obligations.
The Current ratio of ERNA (1.58) is worse than 80.19% of its industry peers.
ERNA has a Quick Ratio of 1.58. This is a normal value and indicates that ERNA is financially healthy and should not expect problems in meeting its short term obligations.
ERNA has a Quick ratio of 1.58. This is in the lower half of the industry: ERNA underperforms 79.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.58
Quick Ratio	1.58

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.77% over the past year.
Looking at the last year, ERNA shows a very negative growth in Revenue. The Revenue has decreased by -99.83% in the last year.
The Revenue for ERNA have been decreasing by -50.61% on average. This is quite bad

EPS 1Y (TTM)95.77%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.8%

Revenue 1Y (TTM)-99.83%

Revenue growth 3YN/A

Revenue growth 5Y-50.61%

Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.